RX-108 is under clinical development by Suzhou Neupharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect RX-108’s likelihood of approval (LoA) and phase transition for Recurrent Head And Neck Cancer Squamous Cell Carcinoma took place on 09 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RX-108 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
RX-108 is under development for the treatment of primary hepatocellular carcinoma, locally advanced or metastatic solid tumors including recurrent glioblastoma multiforme and recurrent/metastatic head and neck squamous cell carcinoma. It is administered intravenously and parenteraly. The drug candidate is a sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) inhibitor.
Suzhou Neupharma overview
Suzhou Neupharma operates in pharmaceutical and healthcare industry. It is headquartered in China.
Quick View RX-108 LOA Data
|Highest Development Stage|